Dr. Joe Oakley is the medical director of biomarker development at Paige and a pathologist with board certification in anatomic, clinical and molecular genetic pathology. His work experience ranges from academic clinical practice to the pharmaceutical and information technology industries. He has overseen and directed development of liquid biopsy, molecular and immunohistochemistry assays for both diagnostic and therapy predictive applications for personalization of medicine. His goal is to link mechanistic understanding of metastasis and clonal evolution in tumor pathology to personalize patient therapy and bring superior regimens to the clinic.
Prior to joining Paige, Dr. Oakley was Associate Vice President / Medical Fellow at Eli Lilly where he oversaw molecular pathology assay development for the diagnostic and experimental pathology group. He also previously served as a pathologist, medical director of clinical molecular diagnostics, and associate professor at Marshall University.
“Precision medicine” is a term we have heard a lot over the last two decades, promising to improve health outcomes by pairing the patient with the right treatment. In cancer, we do this primarily with biomarkers. Our understanding of biomarkers – signatures of key features of a tumor – and their role in disease has […]